Lysosomal Therapeutics
4
14M
4
0.40
1
- Areas of investment
Summary
Lysosomal Therapeutics appeared to be the Corporate Investor, which was created in 2014. The venture was found in North America in United States. The main office of represented Corporate Investor is situated in the Cambridge.
The fund has specific favorite in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Aura Biosciences, Artax Biopharma, NanoString Technologies. We can highlight the next thriving fund investment areas, such as Neuroscience, Biotechnology. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year. This Lysosomal Therapeutics works on 4 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2013. The important activity for fund was in 2015.
The usual cause for the fund is to invest in rounds with 4 partakers. Despite the Lysosomal Therapeutics, startups are often financed by Clarus Ventures, Realiza Business Angels, ALS Finding a Cure. The meaningful sponsors for the fund in investment in the same round are Advent Life Sciences, Ysios Capital, OVP Venture Partners. In the next rounds fund is usually obtained by DFJ, Clarus Ventures, Ysios Capital.
The current fund was established by Dimitri Krainc, Edmund Sybertz, Henri Termeer, Joseph Mazzulli, Kees Been, Peter Wirth.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.40
- Investments by industry
- Biotechnology (4)
- Pharmaceutical (2)
- Medical (2)
- Neuroscience (1)
- Health Care (1) Show 3 more
- Investments by region
-
- United States (4)
- Peak activity year
- 2015
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Artax Biopharma | 22 Sep 2015 | Biotechnology, Therapeutics, Biopharma | Early Stage Venture | 10M | United States, Cambridge, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.